Eutilex.Co.Ltd Past Earnings Performance
Past criteria checks 0/6
Eutilex.Co.Ltd's earnings have been declining at an average annual rate of -12%, while the Biotechs industry saw earnings growing at 14.4% annually. Revenues have been declining at an average rate of 21.4% per year.
Key information
-12.0%
Earnings growth rate
-0.9%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -21.4% |
| Return on equity | -47.3% |
| Net Margin | -6,472.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Eutilex.Co.Ltd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 410 | -26,549 | 9,527 | 17,227 |
| 31 Dec 23 | 132 | -27,718 | 9,409 | 18,504 |
| 30 Sep 23 | 229 | -29,233 | 9,222 | 20,749 |
| 30 Jun 23 | 252 | -32,946 | 9,793 | 23,174 |
| 31 Mar 23 | 231 | -32,712 | 10,476 | 23,543 |
| 31 Dec 22 | 216 | -33,427 | 10,142 | 24,640 |
| 30 Sep 22 | 135 | -34,018 | 9,617 | 23,716 |
| 30 Jun 22 | 95 | -29,236 | 8,901 | 23,032 |
| 31 Mar 22 | 73 | -28,192 | 8,254 | 23,236 |
| 31 Dec 21 | 74 | -29,575 | 7,733 | 24,155 |
| 30 Sep 21 | 1,211 | -29,478 | 7,895 | 25,133 |
| 30 Jun 21 | 1,255 | -31,389 | 7,716 | 24,425 |
| 31 Mar 21 | 1,963 | -32,957 | 7,276 | 21,750 |
| 31 Dec 20 | 2,036 | -28,768 | 7,312 | 18,219 |
| 30 Sep 20 | 988 | -24,067 | 7,283 | 14,895 |
| 30 Jun 20 | 1,019 | -22,301 | 7,982 | 12,322 |
| 31 Mar 20 | 405 | -18,584 | 8,085 | 10,986 |
| 31 Dec 19 | 409 | -17,131 | 7,907 | 9,802 |
| 30 Sep 19 | 412 | -17,070 | 8,634 | 8,249 |
| 30 Jun 19 | 407 | -15,562 | 9,650 | 6,229 |
| 31 Mar 19 | 404 | -14,103 | 9,213 | 5,206 |
| 31 Dec 18 | 402 | -13,233 | 7,715 | 5,585 |
| 30 Sep 18 | 389 | -11,611 | 6,581 | 5,279 |
| 30 Jun 18 | 326 | -10,879 | 4,634 | 6,097 |
| 31 Mar 18 | 231 | -10,383 | 4,652 | 5,261 |
| 31 Dec 17 | 133 | -9,593 | 5,695 | 3,582 |
Quality Earnings: A263050 is currently unprofitable.
Growing Profit Margin: A263050 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A263050 is unprofitable, and losses have increased over the past 5 years at a rate of 12% per year.
Accelerating Growth: Unable to compare A263050's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A263050 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.4%).
Return on Equity
High ROE: A263050 has a negative Return on Equity (-47.31%), as it is currently unprofitable.